Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program, intended to ...

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients in its mid-stage study of CK-4021586 (CK-586), a ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program ...

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

View Our Latest Stock Analysis on CYTK Cytokinetics Stock Performance CYTK opened at $49.94 on Tuesday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of ...

Cytokinetics Price Performance Shares of NASDAQ:CYTK opened at $49.94 on Tuesday. The company has a market cap of $5.89 billion, a P/E ratio of -9.28 and a beta of 0.82. The business has a fifty ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks ...